ABL1 is an inclusion eligibility criterion in 11 clinical trials for mantle cell lymphoma, of which 5 are open and 6 are closed. Of the trials that contain ABL1 status and mantle cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open), 4 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), 4 are phase 2 (1 open), and 1 is no phase specified (0 open) [3].

AFF1 is an inclusion eligibility criterion in 8 clinical trials for mantle cell lymphoma, of which 3 are open and 5 are closed. Of the trials that contain AFF1 status and mantle cell lymphoma as inclusion criteria, 4 are phase 1 (2 open), 3 are phase 2 (1 open), and 1 is no phase specified (0 open) [3].

ALK is an inclusion eligibility criterion in 3 clinical trials for mantle cell lymphoma, of which 2 are open and 1 is closed. Of the trials that contain ALK status and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (1 open) [3].

ARID1A is an inclusion eligibility criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ARID1A status and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

ASXL1 is an inclusion eligibility criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ASXL1 status and mantle cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open) [3].

ATM is an inclusion eligibility criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ATM status and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

ATR is an inclusion eligibility criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ATR status and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

ATRX is an inclusion eligibility criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ATRX status and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

BAP1 is an inclusion eligibility criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains BAP1 status and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

BARD1 is an inclusion eligibility criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains BARD1 status and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

BCL2 is an inclusion eligibility criterion in 11 clinical trials for mantle cell lymphoma, of which 9 are open and 2 are closed. Of the trials that contain BCL2 status and mantle cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open), 6 are phase 1 (4 open), and 4 are phase 1/phase 2 (4 open) [3].

BCL6 is an inclusion eligibility criterion in 10 clinical trials for mantle cell lymphoma, of which 8 are open and 2 are closed. Of the trials that contain BCL6 status and mantle cell lymphoma as inclusion criteria, 6 are phase 1 (4 open) and 4 are phase 1/phase 2 (4 open) [3].

BCR is an inclusion eligibility criterion in 11 clinical trials for mantle cell lymphoma, of which 5 are open and 6 are closed. Of the trials that contain BCR status and mantle cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open), 4 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), 4 are phase 2 (1 open), and 1 is no phase specified (0 open) [3].

BRCA1 is an inclusion eligibility criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA1 status and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

BRCA2 is an inclusion eligibility criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA2 status and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

BRIP1 is an inclusion eligibility criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains BRIP1 status and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

BTK is an inclusion eligibility criterion in 1 clinical trial for mantle cell lymphoma, of which 0 are open and 1 is closed. Of the trial that contains BTK status and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].

C11orf30 is an inclusion eligibility criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains C11orf30 status and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

CBFB is an inclusion eligibility criterion in 1 clinical trial for mantle cell lymphoma, of which 0 are open and 1 is closed. Of the trial that contains CBFB status and mantle cell lymphoma as inclusion criteria, 1 is no phase specified (0 open) [3].

CCND1 is an inclusion eligibility criterion in 31 clinical trials for mantle cell lymphoma, of which 27 are open and 4 are closed. Of the trials that contain CCND1 status and mantle cell lymphoma as inclusion criteria, 9 are phase 1 (6 open), 6 are phase 1/phase 2 (6 open), 13 are phase 2 (12 open), and 3 are phase 3 (3 open) [3].

Ibrutinib has evidence of efficacy in patients with CCND1 mutation in mantle cell lymphoma [3].

CDK12 is an inclusion eligibility criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CDK12 status and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

CHEK1 is an inclusion eligibility criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CHEK1 status and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

CHEK2 is an inclusion eligibility criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CHEK2 status and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

DEK is an inclusion eligibility criterion in 8 clinical trials for mantle cell lymphoma, of which 3 are open and 5 are closed. Of the trials that contain DEK status and mantle cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open), 4 are phase 1 (2 open), 2 are phase 2 (0 open), and 1 is no phase specified (0 open) [3].

ELL is an inclusion eligibility criterion in 7 clinical trials for mantle cell lymphoma, of which 2 are open and 5 are closed. Of the trials that contain ELL status and mantle cell lymphoma as inclusion criteria, 4 are phase 1 (2 open), 2 are phase 2 (0 open), and 1 is no phase specified (0 open) [3].

ERCC2 is an inclusion eligibility criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ERCC2 status and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

ERCC3 is an inclusion eligibility criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ERCC3 status and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

ERCC4 is an inclusion eligibility criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ERCC4 status and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

ERCC5 is an inclusion eligibility criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ERCC5 status and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

ERCC6 is an inclusion eligibility criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ERCC6 status and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCA is an inclusion eligibility criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FANCA status and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCB is an inclusion eligibility criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FANCB status and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCC is an inclusion eligibility criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FANCC status and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCD2 is an inclusion eligibility criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FANCD2 status and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCE is an inclusion eligibility criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FANCE status and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCF is an inclusion eligibility criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FANCF status and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCG is an inclusion eligibility criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FANCG status and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCI is an inclusion eligibility criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FANCI status and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCL is an inclusion eligibility criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FANCL status and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCM is an inclusion eligibility criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FANCM status and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FGFR3 is an inclusion eligibility criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 status and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FLT3 is an inclusion eligibility criterion in 13 clinical trials for mantle cell lymphoma, of which 5 are open and 8 are closed. Of the trials that contain FLT3 status and mantle cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open), 5 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), 5 are phase 2 (1 open), and 1 is no phase specified (0 open) [3].

HDAC1 is an inclusion eligibility criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains HDAC1 status and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

HDAC2 is an inclusion eligibility criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains HDAC2 status and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

HRAS is an inclusion eligibility criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains HRAS status and mantle cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open) [3].

IGH is an inclusion eligibility criterion in 32 clinical trials for mantle cell lymphoma, of which 28 are open and 4 are closed. Of the trials that contain IGH status and mantle cell lymphoma as inclusion criteria, 9 are phase 1 (6 open), 6 are phase 1/phase 2 (6 open), 14 are phase 2 (13 open), and 3 are phase 3 (3 open) [3].

Ibrutinib has evidence of efficacy in patients with IGH mutation in mantle cell lymphoma [3].

IKZF1 is an inclusion eligibility criterion in 3 clinical trials for mantle cell lymphoma, of which 1 is open and 2 are closed. Of the trials that contain IKZF1 status and mantle cell lymphoma as inclusion criteria, 3 are phase 2 (1 open) [3].

IRAK1 is an inclusion eligibility criterion in 1 clinical trial for mantle cell lymphoma, of which 0 are open and 1 is closed. Of the trial that contains IRAK1 status and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].

IRF4 is an inclusion eligibility criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains IRF4 status and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

JAK2 is an inclusion eligibility criterion in 2 clinical trials for mantle cell lymphoma, of which 1 is open and 1 is closed. Of the trials that contain JAK2 status and mantle cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open) and 1 is phase 1 (0 open) [3].

JAK3 is an inclusion eligibility criterion in 1 clinical trial for mantle cell lymphoma, of which 0 are open and 1 is closed. Of the trial that contains JAK3 status and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].

KIT is an inclusion eligibility criterion in 2 clinical trials for mantle cell lymphoma, of which 1 is open and 1 is closed. Of the trials that contain KIT status and mantle cell lymphoma as inclusion criteria, 1 is phase 2 (1 open) and 1 is no phase specified (0 open) [3].

KMT2A is an inclusion eligibility criterion in 10 clinical trials for mantle cell lymphoma, of which 5 are open and 5 are closed. Of the trials that contain KMT2A status and mantle cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open), 4 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), 3 are phase 2 (1 open), and 1 is no phase specified (0 open) [3].

KRAS is an inclusion eligibility criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and mantle cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open) [3].

MAF is an inclusion eligibility criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MAF status and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MAFB is an inclusion eligibility criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MAFB status and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MDM2 is an inclusion eligibility criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MDM2 status and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MDM4 is an inclusion eligibility criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MDM4 status and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MECOM is an inclusion eligibility criterion in 11 clinical trials for mantle cell lymphoma, of which 6 are open and 5 are closed. Of the trials that contain MECOM status and mantle cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open), 4 are phase 1 (2 open), 5 are phase 2 (3 open), and 1 is no phase specified (0 open) [3].

MLF1 is an inclusion eligibility criterion in 6 clinical trials for mantle cell lymphoma, of which 4 are open and 2 are closed. Of the trials that contain MLF1 status and mantle cell lymphoma as inclusion criteria, 2 are phase 1 (1 open) and 4 are phase 2 (3 open) [3].

MLH1 is an inclusion eligibility criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MLH1 status and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MLH3 is an inclusion eligibility criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MLH3 status and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MLLT1 is an inclusion eligibility criterion in 7 clinical trials for mantle cell lymphoma, of which 2 are open and 5 are closed. Of the trials that contain MLLT1 status and mantle cell lymphoma as inclusion criteria, 4 are phase 1 (2 open), 2 are phase 2 (0 open), and 1 is no phase specified (0 open) [3].

MLLT10 is an inclusion eligibility criterion in 7 clinical trials for mantle cell lymphoma, of which 2 are open and 5 are closed. Of the trials that contain MLLT10 status and mantle cell lymphoma as inclusion criteria, 4 are phase 1 (2 open), 2 are phase 2 (0 open), and 1 is no phase specified (0 open) [3].

MLLT3 is an inclusion eligibility criterion in 7 clinical trials for mantle cell lymphoma, of which 2 are open and 5 are closed. Of the trials that contain MLLT3 status and mantle cell lymphoma as inclusion criteria, 4 are phase 1 (2 open), 2 are phase 2 (0 open), and 1 is no phase specified (0 open) [3].

MLLT4 is an inclusion eligibility criterion in 7 clinical trials for mantle cell lymphoma, of which 2 are open and 5 are closed. Of the trials that contain MLLT4 status and mantle cell lymphoma as inclusion criteria, 4 are phase 1 (2 open), 2 are phase 2 (0 open), and 1 is no phase specified (0 open) [3].

MRE11A is an inclusion eligibility criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MRE11A status and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MSH2 is an inclusion eligibility criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MSH2 status and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MSH3 is an inclusion eligibility criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MSH3 status and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MSH6 is an inclusion eligibility criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MSH6 status and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MUTYH is an inclusion eligibility criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MUTYH status and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MYC is an inclusion eligibility criterion in 11 clinical trials for mantle cell lymphoma, of which 9 are open and 2 are closed. Of the trials that contain MYC status and mantle cell lymphoma as inclusion criteria, 6 are phase 1 (4 open) and 5 are phase 1/phase 2 (5 open) [3].

MYCN is an inclusion eligibility criterion in 1 clinical trial for mantle cell lymphoma, of which 0 are open and 1 is closed. Of the trial that contains MYCN status and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].

MYD88 is an inclusion eligibility criterion in 1 clinical trial for mantle cell lymphoma, of which 0 are open and 1 is closed. Of the trial that contains MYD88 status and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].

MYH11 is an inclusion eligibility criterion in 1 clinical trial for mantle cell lymphoma, of which 0 are open and 1 is closed. Of the trial that contains MYH11 status and mantle cell lymphoma as inclusion criteria, 1 is no phase specified (0 open) [3].

NBN is an inclusion eligibility criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains NBN status and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

NOTCH1 is an inclusion eligibility criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains NOTCH1 status and mantle cell lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

NOTCH2 is an inclusion eligibility criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains NOTCH2 status and mantle cell lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

NPM1 is an inclusion eligibility criterion in 8 clinical trials for mantle cell lymphoma, of which 4 are open and 4 are closed. Of the trials that contain NPM1 status and mantle cell lymphoma as inclusion criteria, 3 are phase 1 (1 open) and 5 are phase 2 (3 open) [3].

NRAS is an inclusion eligibility criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and mantle cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open) [3].

NRIP3 is an inclusion eligibility criterion in 7 clinical trials for mantle cell lymphoma, of which 2 are open and 5 are closed. Of the trials that contain NRIP3 status and mantle cell lymphoma as inclusion criteria, 4 are phase 1 (2 open), 2 are phase 2 (0 open), and 1 is no phase specified (0 open) [3].

NUP214 is an inclusion eligibility criterion in 8 clinical trials for mantle cell lymphoma, of which 3 are open and 5 are closed. Of the trials that contain NUP214 status and mantle cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open), 4 are phase 1 (2 open), 2 are phase 2 (0 open), and 1 is no phase specified (0 open) [3].

PALB2 is an inclusion eligibility criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains PALB2 status and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

PARP1 is an inclusion eligibility criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains PARP1 status and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

PARP2 is an inclusion eligibility criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains PARP2 status and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

PBX1 is an inclusion eligibility criterion in 8 clinical trials for mantle cell lymphoma, of which 4 are open and 4 are closed. Of the trials that contain PBX1 status and mantle cell lymphoma as inclusion criteria, 4 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 3 are phase 2 (1 open) [3].

PLCG2 is an inclusion eligibility criterion in 1 clinical trial for mantle cell lymphoma, of which 0 are open and 1 is closed. Of the trial that contains PLCG2 status and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].

PML is an inclusion eligibility criterion in 1 clinical trial for mantle cell lymphoma, of which 0 are open and 1 is closed. Of the trial that contains PML status and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].

PMS1 is an inclusion eligibility criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains PMS1 status and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

PMS2 is an inclusion eligibility criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains PMS2 status and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

POLD1 is an inclusion eligibility criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains POLD1 status and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

POLE is an inclusion eligibility criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains POLE status and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

POLQ is an inclusion eligibility criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains POLQ status and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

PPP2R1A is an inclusion eligibility criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains PPP2R1A status and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

PPP2R2A is an inclusion eligibility criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains PPP2R2A status and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

PRKDC is an inclusion eligibility criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains PRKDC status and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

RAD50 is an inclusion eligibility criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains RAD50 status and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

RAD51 is an inclusion eligibility criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51 status and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

RAD51B is an inclusion eligibility criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51B status and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

RAD51C is an inclusion eligibility criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51C status and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

RAD51D is an inclusion eligibility criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51D status and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

RAD54L is an inclusion eligibility criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains RAD54L status and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

RARA is an inclusion eligibility criterion in 1 clinical trial for mantle cell lymphoma, of which 0 are open and 1 is closed. Of the trial that contains RARA status and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].

RPN1 is an inclusion eligibility criterion in 11 clinical trials for mantle cell lymphoma, of which 6 are open and 5 are closed. Of the trials that contain RPN1 status and mantle cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open), 4 are phase 1 (2 open), 5 are phase 2 (3 open), and 1 is no phase specified (0 open) [3].

RUNX1 is an inclusion eligibility criterion in 2 clinical trials for mantle cell lymphoma, of which 1 is open and 1 is closed. Of the trials that contain RUNX1 status and mantle cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open) and 1 is no phase specified (0 open) [3].

RUNX1T1 is an inclusion eligibility criterion in 1 clinical trial for mantle cell lymphoma, of which 0 are open and 1 is closed. Of the trial that contains RUNX1T1 status and mantle cell lymphoma as inclusion criteria, 1 is no phase specified (0 open) [3].

SLX4 is an inclusion eligibility criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains SLX4 status and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

SMARCB1 is an inclusion eligibility criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains SMARCB1 status and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

STAG2 is an inclusion eligibility criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains STAG2 status and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

STK11 is an inclusion eligibility criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains STK11 status and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

TCF3 is an inclusion eligibility criterion in 8 clinical trials for mantle cell lymphoma, of which 4 are open and 4 are closed. Of the trials that contain TCF3 status and mantle cell lymphoma as inclusion criteria, 4 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 3 are phase 2 (1 open) [3].

TP53 is an inclusion eligibility criterion in 12 clinical trials for mantle cell lymphoma, of which 7 are open and 5 are closed. Of the trials that contain TP53 status and mantle cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open), 4 are phase 1 (2 open), 5 are phase 2 (3 open), 1 is phase 3 (1 open), and 1 is no phase specified (0 open) [3].

TYK2 is an inclusion eligibility criterion in 1 clinical trial for mantle cell lymphoma, of which 0 are open and 1 is closed. Of the trial that contains TYK2 status and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].

WHSC1 is an inclusion eligibility criterion in 2 clinical trials for mantle cell lymphoma, of which 2 are open and 0 are closed. Of the trials that contain WHSC1 status and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

XRCC1 is an inclusion eligibility criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains XRCC1 status and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].